365572-61-8

Upstream product

• 106-41-2 4-bromo-phenol 
• 154669-49-5 [(S)-2-oxooxazolidin-4-yl]methyl-4-methylbenzenesulfonate 

Downstream Products

• 365572-70-9 3-{(3E)(2S)-3-aza-2-[(4-bromophenyl)methyl]-4-(4-methoxyphenyl)but-3-enyl}-5,5-dimethyl-1,3-diazolidine-2,4-dione 
• 361547-40-2 3-[(2S)-3-(4-bromophenoxy)-2-(hydroxyamino)propyl]-5,5-dimethyl-1,3-diazolidine-2,4-dione 
• 365572-69-6 (3E)(2S)-3-aza-2-[(4-bromophenyl)methyl]-4-(4-methoxyphenyl)but-3-en-1-ol 
• 220616-11-5 3-((2S)-2-(N-hydroxyamino)-3-((4'-(trifluoromethoxy)(1,1'-biphenyl)-4-yl)oxy)propyl)-5,5-dimethyl-2,4-imidazolidinedione 
• 365572-68-5 (2S)-2-amino-3-(4-bromophenoxy)propan-1-ol 

Relevant academic research and scientific papers

Synthesis of [14C]ABT-770, matrix metalloproteinase inhibitor (MMPI), labelled in the phenoxy ring

The MMPI [14C]ABT-770 (1), N-[(1S)-1-[(4,4-Dimethyl-2,5-dioxo-1-imidazolidinyl)methyl]]-2-[[4′ -(trifluoromethoxy)[1,1′-biphenyl]-4-yl]oxy]ethyl]-N-hydroxyformamide was synthesized in 8 steps using 4-bromophenol-UL-14C (10) as a star

Process for the preparation of matrix metalloproteinase inhibitors

The instant invention provides a process for the synthesis of matrix metalloproteinase inhibitors.